Structure Therapeutics Reports Positive Topline Data From Phase 2 Access Ii Trial With Once-Daily Oral Small Molecule Glp-1 Receptor Agonist, Aleniglipron

March 16 (Reuters) - Structure Therapeutics Inc GPCR.O:

• STRUCTURE THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM PHASE 2 ACCESS II TRIAL WITH ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST, ALENIGLIPRON

• STRUCTURE THERAPEUTICS INC - ACCESS II SHOWS PLACEBO-ADJUSTED MEAN WEIGHT LOSS OF 16.3% AT 180 MG AND 16.0% AT 240 MG AT 44 WEEKS

• STRUCTURE THERAPEUTICS INC - END-OF-PHASE 2 FDA MEETING SCHEDULED FOR Q2 2026; PHASE 3 INITIATION ON TRACK FOR 2H 2026

• STRUCTURE THERAPEUTICS INC - ACCESS OLE STUDY SHOWS CONTINUED WEIGHT LOSS UP TO 16.2% WITH 120 MG AT 56 WEEKS

• STRUCTURE THERAPEUTICS INC - INTERIM DATA SHOWS 2.0%-3.4% AE-RELATED DISCONTINUATIONS WITH 2.5 MG STARTING DOSE